| Price | $163.21 |
| Year Range | $154.6 – $207.08 |
| Market Cap | $248B |
| PE Ratio | 23.98 |
| Industry | Drug Manufacturers |
What Is Astrazeneca’s AI Stock Analysis?
Astrazeneca’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Astrazeneca’s momentum in near-real time.
Astrazeneca (AZN) has an AltIndex AI Score of 58/100, currently a Hold signal. The AI Score distills Astrazeneca's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
Astrazeneca’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of Astrazeneca — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving AZN’s AI Score?
Fundamentals
Revenue for the last quarter was $15.4B. This is an increase of 0.63% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of 6.41%, suggesting positive year-over-year growth. Net income for the last quarter was $2.51B. This represents a decrease of 18.60% compared to the quarter before it, indicating a need for concern. Compared to the same quarter last year, there is an increase of 2.33%, suggesting positive year-over-year growth. Ebitda for the last quarter was $5.16B. This represents a decrease of 8.99% compared to the quarter before it, indicating a need for concern. Compared to the same quarter last year, there is an increase of 4.20%, suggesting positive year-over-year growth. The current P/E ratio is 23.98. This appears to be within a normal range, neither particularly high nor low.
See Astrazeneca’s earnings and insider transactions.
Technicals
Today's stock price is $163.21. This is an increase of 4.32% compared to a month ago, indicating a positive short-term trend. Compared to a year ago, there is an increase of 8.13%, suggesting a positive long-term trend. The trend is bullish. The current SMA10 is $160.95, which is higher than the previous SMA10 of $160.90. This indicates a potential upward trend in price movement. The RSI is 45.8, indicating a neutral condition.
See the full technical analysis and price prediction.
Alternative data
Astrazeneca has an estimated 1,002 open positions. This number is down by -22% in the last couple of months, indicating a company trying to improve its margins or cut costs. Not a great sign for a growing company. The business outlook among employees at Astrazeneca is neutral. Astrazeneca has an estimate of 1.1M visitors to their webpage. The number of visitors is up by 16% in the last couple of months, a bullish trend as this can indicate can increase in customers.
Explore Astrazeneca’s job postings, web traffic and app downloads.
Sentiment & social
Astrazeneca has 100,000 followers on their Instagram page, with no meaningful increase or decrese in the last couple of months. Astrazeneca has 290,000 followers on their Twitter page. The number of followers is down by -0% in the last couple of months, indicating a loss in interest in the company.
Track Astrazeneca’s market sentiment.
Frequently Asked Questions: Astrazeneca AI Stock Analysis
Astrazeneca's AltIndex AI Score is 58/100, currently a Hold signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates Astrazeneca a Hold (58/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of Astrazeneca — company overview, fundamentals, technicals and alternative data, with a recommendation. See the AZN AI Score or sign up to read the full thesis.
